Highly anticipated HIV vaccine fails in large trial


The only HIV vaccine nearing the completion of testing trials is not effective at preventing HIV, officials announced Wednesday.

The vaccine had been in development since 2019 and was given to 3,900 study participants through October 2022, but data shows it does not protect against HIV compared with a placebo, according to developer Janssen Pharmaceutical.

Experts estimate the failure means there won’t be another potential vaccine on the horizon for 3 to 5 years, the New York Times reported.

“It’s obviously disappointing,” Anthony Fauci, MD, former head of the National Institute of Allergy and Infectious Diseases, told MSNBC, noting that other areas of HIV treatment research are promising. “I don’t think that people should give up on the field of the HIV vaccine.”

No safety issues had been identified with the vaccine during the trial, which studied the experimental treatment in men who have sex with men or with transgender people.

There is no cure for HIV, but disease progression can be managed with existing treatments. HIV attacks the body’s immune system and destroys white blood cells, increasing the risk of other infections. More than 1.5 million people worldwide were infected with HIV in 2021 and 38.4 million people are living with the virus, according to UNAIDS.

A version of this article first appeared on WebMD.com.

Recommended Reading

CAB-LA’s full potential for HIV prevention hits snags
MDedge Infectious Disease
HIV vaccine trial makes pivotal leap toward making ‘super antibodies’
MDedge Infectious Disease
Systematic review supports preferred drugs for HIV in youths
MDedge Infectious Disease
FDA approves first-in-class drug for HIV
MDedge Infectious Disease
Kaposi’s sarcoma: Antiretroviral-related improvements in survival measured
MDedge Infectious Disease